Search research articles
Contact Us
Filters
Showing results (11-20 of 13) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 13 results.
Molecular Cancer Therapeutics
|
June 16, 2011
Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors
Wenle Xia, Zuguo Liu, Rongrong Zong, et al.
Plos One
|
September 2, 2016
X-Ray Psoralen Activated Cancer Therapy (X-PACT)
Mark Oldham, Paul Yoon, Zak Fathi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 3, 2005
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
Neil L Spector, Wenle Xia, Howard Burris, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 13) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 13 results.
Molecular Cancer Therapeutics
|
June 16, 2011
Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors
Wenle Xia, Zuguo Liu, Rongrong Zong, et al.
Plos One
|
September 2, 2016
X-Ray Psoralen Activated Cancer Therapy (X-PACT)
Mark Oldham, Paul Yoon, Zak Fathi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 3, 2005
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
Neil L Spector, Wenle Xia, Howard Burris, et al.
Page
of 2